喜炎平注射液上市后医院集中监测临床应用分析  

Analysis of clinical use of post-marketing hospital centralized monitoring of Xiyanping injection

作　　者：赵瑛[1] 史琛[1] 黄璞[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院药剂科,湖北武汉430022

出　　处：《中国中药杂志》2016年第4期743-747,共5页China Journal of Chinese Materia Medica

基　　金：国家科技支撑计划项目(2006038086056)

摘　　要：医院集中监测是药物临床安全性评价中主动监测的方法之一。喜炎平注射液至今已上市30余年,用于支气管炎、扁桃体炎、细菌性痢疾等,但其上市后的安全性、有效性监测研究报道较少。笔者对喜炎平注射液上市后临床应用情况进行综合评价,为规范和指导临床合理用药、完善使用说明书和使用方案提供依据。该研究采用医院集中监测的方法,选取某院2014年1月至2014年12月入院并使用喜炎平注射液的住院患者为研究对象,记录患者的基本情况、药品使用和不良反应发生情况,并进行数据统计分析。共观察病例848份,其中用药目的不符的占39.9%;成人和儿童用法用量不合理的占比分别为1.72%,6.62%;溶媒选择不当的占3.18%;给药途径为静脉滴注或雾化给药均为合理;同瓶混用药物的占2.24%;有1例发生不良反应,发生率为0.12%。研究表明该院喜炎平注射液临床应用欠规范,应加强其使用的规范化管理,对主要科室进行针对性的用药指导;研究同时发现说明书中成人用法用量项信息不全,建议生产厂家进行相关临床研究,完善药品说明书"用法用量"项下信息,以提高喜炎平注射液临床应用的安全性和有效性。To assess the clinical use and occurrence of adverse reactions of Xiyanping injection,and to provide reference for rational drug use in the clinic. Based on hospital central monitoring method,the clinical data of Xiyanping injection in our hospital in 2014 was tracked and analyzed. A total of 848 inpatients were enrolled in this study. Among them,39. 9% were not in accordance with the medication purpose. In practice,the dose more than the limits prescribed by the instructions of child and adult were accounted for 1. 72%and 6. 62%,respectively; improper choice of solvent,accounting for 3. 18%; both the choice of of versus intravenous drip and aerosol inhalati administration route were reasonable; mixed with other drug,accounting for 2. 24%. The incidence of ADR of Xiyanping injection was 0. 12%,which showed good safety. Irrational use of Xiyanping injection existed in clinics,and the use should be strengthened and regulated. The manufacturer should improve the drug instruction of usage and dosage.

关 键 词：喜炎平注射液 医院集中监测 上市后再评价 临床应用 不良反应 

分 类 号：R288[医药卫生—中药学]